Article Versions Notes

Feng T, Liu M, Zhong D, Xu X, Luo Z, Zhang W, Wang Y, Chen R, Chen X, Ma G. Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications. Antioxidants. 2026; 15(5):543. https://doi.org/10.3390/antiox15050543

Feng, Taoshan, Meilian Liu, Dan Zhong, Xusan Xu, Zhengqiang Luo, Wensen Zhang, Yajun Wang, Riling Chen, Xiaoming Chen, and Guoda Ma. 2026. "Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications" Antioxidants 15, no. 5: 543. https://doi.org/10.3390/antiox15050543

Feng, T., Liu, M., Zhong, D., Xu, X., Luo, Z., Zhang, W., Wang, Y., Chen, R., Chen, X., & Ma, G. (2026). Empagliflozin Ameliorates Diabetic Cardiomyopathy by Inhibiting Ferroptosis via SIRT3: Mechanisms and Therapeutic Implications. Antioxidants, 15(5), 543. https://doi.org/10.3390/antiox15050543